Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER

(PFE)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/09/2019 10/10/2019 10/11/2019 10/14/2019 10/15/2019 Date
35.69(c) 35.79(c) 36.11(c) 36.3(c) 36.5(c) Last
12 954 607 11 720 794 17 523 655 8 417 230 14 419 744 Volume
+0.73% +0.28% +0.89% +0.53% +0.55% Change
More quotes
Financials (USD)
Sales 2019 51 516 M
EBIT 2019 18 890 M
Net income 2019 12 971 M
Debt 2019 32 534 M
Yield 2019 3,93%
Sales 2020 47 612 M
EBIT 2020 17 717 M
Net income 2020 11 013 M
Debt 2020 30 967 M
Yield 2020 4,03%
P/E ratio 2019 16,0x
P/E ratio 2020 16,1x
EV / Sales2019 4,55x
EV / Sales2020 4,89x
Capitalization 202 B
More Financials
Company
Pfizer the world's leading pharmaceutical group. Net sales break down by family of products as follows: - vaccines, oncology products and consumer medicines (59.8%); - generic medicines (40.2%): for treating cardio-vascular diseases, nervous system disorders, infectious and respiratory diseases,... 
Sector
Pharmaceuticals
Calendar
10/29Earnings Release
More about the company
Surperformance© ratings of Pfizer
Trading Rating : Investor Rating :
More Ratings
Latest news on PFIZER
10/15Health-Care Stocks Get a Welcome Respite -- Update
DJ
10/15Health-Care Stocks Get a Welcome Respite
DJ
10/15Elizabeth Warren's Rise Is Battering Health-Care Stocks
DJ
10/15Elizabeth Warren's Rise Is Battering Health-Care Stocks
DJ
10/14Health Care Flat As Traders Seek Out Defensive Sectors -- Health Care Roundup
DJ
10/14PFIZER : Presents Positive Phase 3 Data at the 28th Congress of the European Aca..
AQ
10/14PFIZER : ImaginAb signs multi-party collaboration agreement with three global ph..
PR
10/12PFIZER : Presents Positive Phase 3 Data at the 28th Congress of the European Aca..
BU
10/07Akcea Therapeutics Shares Up 44% on Pfizer Licensing Agreement
DJ
10/04Clarityne Market to See Major Growth by 2025 | Merck & Co, Bayer, Perrigo, Ap..
AQ
10/02IDWEEK 2019 : ViiV Healthcare to present 20 abstracts from its innovative R&D po..
AQ
10/01PFIZER : Emirates, Pfizer Upjohn and UAE Ministry of Health & Prevention Partner..
AQ
10/01BIOGEN : Names Sandrock Head of R&D As Ehlers Steps Down
DJ
09/30PFIZER : 4D Molecular Therapeutics Files for IPO, Applies to List on Nasdaq
DJ
09/30PFIZER : Presents Interim Analysis Results from Phase 3 BEACON CRC trial of BRAF..
AQ
More news
News in other languages on PFIZER
10/10AKTIE IM FOKUS : Gerresheimer leiden unter durchwachsenen Quartalszahlen
09/29Union für nationale Arzneimittelreserve
09/27PFIZER : résultats positifs sur l'Abrocitinib
09/27Wall Street hésite après des indicateurs mitigés
09/27WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
More news
Analyst Recommendations on PFIZER
More recommendations
Sector news : Pharmaceuticals - NEC
08:42aMARKET SNAPSHOT: Stock Futures Slightly Lower As Worries Remain Over U.S.-Chi..
DJ
08:14aACHILLION PHARMACEUTICALS : Shares Up 84% on Buyout Deal
DJ
07:52aINCYTE : Says Phase 3 REACH2 Trial Meets Endpoint
DJ
07:27aELI LILLY AND : Phase 3 Pegilodecakin Study Misses Main Endpoint in Pancreatic C..
DJ
07:10aALEXION PHARMACEUTICALS : Buys Achillion Pharma for $930 Million
DJ
More sector news : Pharmaceuticals - NEC
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 43,50  $
Last Close Price 36,50  $
Spread / Highest target 50,7%
Spread / Average Target 19,2%
Spread / Lowest Target 1,37%
EPS Revisions
Managers
NameTitle
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Mikael Dolsten Chief Scientific Officer
Lidia L. Fonseca Chief Technology Officer & EVP
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-16.38%201 883
JOHNSON & JOHNSON1.29%350 587
ROCHE HOLDING AG19.25%248 542
MERCK AND COMPANY11.29%217 734
NOVARTIS16.20%198 243
AMGEN5.13%122 735